uniQure (NASDAQ:QURE – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Raymond James upgraded the stock from an outperform rating to a strong-buy rating. Raymond James now has a $52.00 price target on the stock, up from their previous price target of $20.00. uniQure traded as high as $17.39 and last traded at $15.30, with a volume of 61370594 shares trading hands. The stock had previously closed at $7.30.
QURE has been the subject of several other reports. Cantor Fitzgerald increased their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday. StockNews.com raised shares of uniQure to a “sell” rating in a report on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. The Goldman Sachs Group cut their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $27.33.
Read Our Latest Stock Report on uniQure
Institutional Investors Weigh In On uniQure
uniQure Price Performance
The stock has a market cap of $745.72 million, a PE ratio of -1.47 and a beta of 0.89. The firm’s fifty day moving average price is $6.20 and its 200 day moving average price is $6.08. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.
uniQure (NASDAQ:QURE – Get Free Report) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts expect that uniQure will post -3.74 EPS for the current fiscal year.
uniQure Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Read More
- Five stocks we like better than uniQure
- When to Sell a Stock for Profit or Loss
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- How to Capture the Benefits of Dividend Increases
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- What Investors Need to Know to Beat the Market
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.